ABCDx

Executive Summary

ABCDx is a Swiss-Spanish diagnostics company developing point-of-care blood tests for brain injuries, such as traumatic brain injury (TBI) and stroke. The company leverages proprietary biomarkers and a Software as a Medical Device (SaMD) platform to enable rapid triage and diagnosis from a simple finger-prick blood sample. This approach addresses a critical unmet need in emergency care, where timely detection of brain injury can significantly improve patient outcomes. By shifting diagnosis from centralized labs to the point of injury or emergency department, ABCDx aims to reduce time to treatment and avoid unnecessary imaging. The company's technology holds the potential to become a standard tool for emergency medical services and hospital systems globally. Founded in 2015 and based in Geneva, ABCDx is privately held and has not disclosed total funding or valuation. The company continues to advance its clinical validation and regulatory clearance processes. With a growing emphasis on decentralized diagnostics and the global burden of brain injuries, ABCDx is well-positioned to capture market share. Key competitive advantages include its novel biomarker panel and integrated software platform, which differentiate it from traditional lab-based and imaging modalities. Successful regulatory approvals and commercial partnerships would be major value inflection points.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for TBI test60% success
• Q4 2026CE marking for stroke detection assay70% success
• Q3 2026Strategic partnership with a major emergency care provider50% success